Last reviewed · How we verify
NCT06078787: PALBOLA
Olaparib in PALB2 Advanced Pancreatic Cancer
Phase 2 trial testing Olaparib 150 MG in Advanced Pancreatic Cancer in 16 participants. Currently enrolling.
1 August 2025
Quick facts
| Lead sponsor | Azienda Ospedaliero-Universitaria di Modena |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 1 August 2023 |
| Primary completion | 1 August 2025 |
| Estimated completion | 1 August 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Olaparib 150 MG — full drug profile →
Conditions studied
- Advanced Pancreatic Cancer — all drugs for Advanced Pancreatic Cancer →
- Metastatic Pancreatic Cancer — all drugs for Metastatic Pancreatic Cancer →
Sponsor
Azienda Ospedaliero-Universitaria di Modena — full company profile →
Who can join
18 and older, any sex, with Advanced Pancreatic Cancer or Metastatic Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase II, non-randomized, multicenter, unblinded open-label study of Olaparib in monotherapy in participants with advanced (locally advanced/metastatic) PALB2-related pancreatic cancer that have progressed after at least one treatment for advanced disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06078787
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Olaparib 150 MG
Trials testing the same drug.
- NCT07069335 — A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Su · Phase 1 · recruiting
- NCT03561870 — Olaparib in Recurrent IDH-mutant Glioma · Phase 2 · completed
Other recruiting trials for Advanced Pancreatic Cancer
Currently open trials in the same condition.
- NCT07416240 — Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer. · EARLY_PHASE1 · recruiting
- NCT07006077 — Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer · Phase 2 · recruiting
- NCT06111274 — A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer · Phase 2 · recruiting
- NCT05916261 — Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer · EARLY_PHASE1 · recruiting
- NCT05380414 — Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients · NA · recruiting
Other Azienda Ospedaliero-Universitaria di Modena trials
Trials by the same sponsor.
- NCT06913530 — European Multicentre Study of Long-term Results Following Visceral Arteries Revascularization: the E-VisAR Study · not yet recruiting
- NCT06883890 — Extended LH Administration · Phase 2 · not yet recruiting
- NCT07245537 — ENDOGYM: A Holistic Approach With Pelvic Floor Physiotherapy and Yoga for Endometriosis Pain Relief · completed
- NCT05922202 — Influence of Frailty on Cardiovascular Events and Mortality in Patients With COPD. · recruiting
- NCT06236568 — Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06078787 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliero-Universitaria di Modena
- Last refreshed: 6 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06078787.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing